AKRO Akero Therapeutics, Inc.

20.91-0.64 (-2.97%)
IEX real time price: 11:54:15 AM

Quote

Previous Close
$21.55
Day Range
$20.51-$21.54
52 Week Range
$16.06-$21.94
Volume
44,205
Avg Volume
274,833
Dividend TTM
-
Ex-Dividend Date
-

Valuation

Market Cap
$565.51M
Enterprise Value (EV)
$506.84M
PE Ratio
-
EV/EBITDA
-36.79
Price/Sales
-
Price/Book
7.79
PEG Ratio
-

Financials

Revenue
-
Gross Profit
-
EBITDA
-$13.78M
EPS, ttm
-
Profit Margin
-
Revenue/Employee
-
Next Earnings Date
8/28/2019 (41 days)
Debt to Equity
-
Debt
$17.31M
Cash
$75.98M
Net Debt
-

Performance

Beta
-1.63
200 Day Moving Avg
$19.02
50 Day Moving Avg
$19.02
52 Week Change
17.63%
YTD Change
14.66%
1 Month Change
17.63%
3 Month Change
17.63%
6 Month Change
17.63%
1 Year Change
17.63%
2 Year Change
-
5 Year Change
-

Share Count

Shares Outstanding
27.0M
Float
-
Restricted Shares
27.0M
Restricted Shares, %
100.00%

Akero Therapeutics, Inc. Company Details

Sector: Health Technology

Industry: Pharmaceuticals: Major

CEO: Andrew Cheng

Website: http://www.akerotx.com

Description: Akero Therapeutics, Inc. operates as a biotechnology company. The firm specializes in transformational treatments for non-alcoholic steatohepatitis (NASH) and other serious metabolic diseases. The company was founded by Jonathan Young and Timothy Rolph on January 24, 2017 and is headquartered in South San Francisco, CA.

Employees: 8